68 results about "Pulmonary metastasis" patented technology

The invention discloses 20 kinds of 5-(bi(3-(2-ethoxy)-1H-indol-2)methyl)-2-hydroxy benzoyl-AA-OBzl, discloses a preparation method of the 5-(bi(3-(2-ethoxy)-1H-indol-2)methyl)-2-hydroxy benzoyl-AA-OBzl, discloses an effect of the 5-(bi(3-(2-ethoxy)-1H-indol-2)methyl)-2-hydroxy benzoyl-AA-OBzl in inhibiting invasion and metastasis of a tumor cell, discloses an activity of the 5-(bi(3-(2-ethoxy)-1H-indol-2)methyl)-2-hydroxy benzoyl-AA-OBzl in inhibiting weight gain of a tumor body of a S180-bearing mouse, and discloses an anti-tumor pulmonary metastasis activity and an anti-inflammatory activity. The compound has an excellent application prospect in preparing an antitumor drug, an anti-tumor metastasis drug and an anti-inflammatory drug.

The invention relates to a passive targeting antitumor prodrug of solid tumor and a preparation method thereof, belonging to the field of antitumor drugs. The preparation method comprises the steps of: reacting small molecules of pectin with Mw of 5,000-45,0000 with doxorubicin to obtain pectin and doxorubicin conjugate with Mw of 100,000-1,000,0000, preparing a suspension, and processing the suspension by using a nano ultra high pressure homogenizing machine to obtain the passive targeting antitumor prodrug of solid tumor with particle diameter of 100-200 nm and melting point of 220-245 DEG C, wherein the pectin and the doxorubicin are connected by an amide bond, the pectin and the pectin are connected by an ester bond formed by condensing the carboxyl group and the hydroxyl group of pectin molecules. The cell inhibition rate of the antitumor prodrug to humanized lung carcinomas cells NCI-H446 and A549 is equivalent to that of the doxorubicin hydrochloride. In the research of the curative effect of melanoma B16 pulmonary metastasis mode mouse, the life cycle of mouse-borne tumor is 42.3+ / -12.4 days, which is remarkably higher than 23.1+ / -10.2 days of the doxorubicin hydrochloride group.

The invention relates to a ursolic acid-aspirin conjugate shown in a formula (I) and application thereof in preparing drugs for preventing tumor metastasis. In vivo experiments verify that the ursolic acid-aspirin conjugate provided by the invention has a remarkable inhibitory effect on adhesion, migration, invasion and the like of tumor cells. in vivo animal experiments verify that the ursolic acid-aspirin conjugate can be used for reducing experimental pulmonary metastasis of 4T1 breast cancer of a rat and showing a relatively good tumor metastasis resisting effect. The ursolic acid-aspirin conjugate provided by the invention can be applied to preventive drugs for tumor metastasis, thereby providing novel selection for developing new drugs for tumor metastasis and preventing postoperative retransfer of malignant tumors. The formula (I) is shown in the description.

The invention provides applications of ursolic acid derivatives in preparation of a drug for preventing and treating tumor metastasis. In-vitro experiments show that the ursolic acid derivatives (US597) has an obvious inhibition effect on the proliferation, adhesion, metastasis and the like of cells, can effectively regulate the expression of adherence factors related to the cell surfaces and the tumor metastasis, and is safe and low-toxic to the normal cells of a human body. In-vivo experiments show that the ursolic acid derivatives can effectively reduce experimental pulmonary metastasis of rat B16-F10 melanin tumor, and is prompted to have better tumor metastasis resistance effect. The ursolic acid derivatives can be applied to a drug for preventing the tumor metastasis, the new applications of the ursolic acid derivatives in preventing and treating tumor are developed, thus providing a new choice for developing a new drug for tumor metastasis so as to prevent the postoperative metastasis of malignant tumor.

The invention discloses a highly metastatic model of human melanoma, a highly metastatic cell subline of the human melanoma, creation methods for the highly metastatic model and the highly metastatic cell subline, and the dynamic detection of metastasis. The subcutaneously-transplanted mouse highly metastatic model and the corresponding cell subline are established in an in-vivo screening way in a mouse with severe combined immune deficiency (SCID) by using mouse lung metastasis, namely human malignant melanoma cell strain A375 pulmonary metastasis, wherein the highly metastatic cell subline of the human melanoma is A375sci, and has a human tumor cell karyotype; and 60 to 75 hypo-triploid-dominated chromosomes are acrocentric and have a heteroploid karyotype. The cell subline has the two routes of metastasis of blood trails and lymph. The in-vivo screening of the highly-metastatic model is performed by using animals with severe immune deficiency, and is expressed and applied in nude mice. A method for detecting Alu genes by using a polymerase chain reaction (PCR) method is simple, highly sensitive and highly specific, and can be used for detecting organ metastasis, particularly micrometastasis, in a human tumor animal-xenotransplantation model.

The invention relates to a detection method for metastatic osteosarcoma molecular targets, a gene combination and a kit. The method has the advantages as follows: the research firstly finds that 1) for the metastatic osteosarcoma, the extracellular vesica based whole transcriptome sequencing finds a molecular characteristic spectrum obviously related to metastasis and has the advantages of noninvasive property, dynamic tracking, and the like, and 2) abundant tumor bio-markers are gathered in the extracellular vesica of metastatic osteosarcoma, and the method has a significance in clinically assessing tumor metastasis and detecting drug targets. The invention designs the gene combination containing 158 genes. According to the gene combination, the driving genes and target genes related to the osteosarcoma pulmonary metastasis can be dynamically monitored after the purification for the blood exosome of the clinic patient and the RNA extraction.

The invention relates to the field of tumor treatment medicine application, and particularly relates to a siRNA dual-interference composition for inhibiting tumor growth and metastasis of breast cancer and application thereof. The siRNA dual-interference composition is prepared by mixing an oligonucleotide VEGF-C-siRNA molecule and an oligonucleotide survivin-siRNA molecule in a mass ratio of (0-2):(2-0), wherein the nucleotide sequence of the oligonucleotide VEGF-C-siRNA molecule has a positive-sense strand of SEQ ID NO.1 and a negative-sense strand of SEQ ID NO.2; and the nucleotide sequence of the oligonucleotide survivin-siRNA molecule has a positive-sense strand of SEQ ID NO.3 and a negative-sense strand of SEQ ID NO.4. The result of an experiment, which is used for inoculating a mouse mammary carcinoma cell line 4T1 in an underarm fat pad of a Balb / c mouse and transfecting a transplanted tumor by using a chemically synthesized and modified oligonucleotide molecule, indicates that the composition of VEGF-C-siRNA and survivin-siRNA can be used for effectively inhibiting growth and pulmonary metastasis of the tumor cells. The chemically synthesized oligonucleotide serving as a novel siRNA anti-tumor drug cannot be easily decomposed, has a relatively high effect half-life, and can be used in in-vitro experiments and in-vivo treatment.

The invention discloses a traditional Chinese medicine composition having anti-lung cancer and anti-liver cancer effects. The traditional Chinese medicine composition is composed of a paris polyphylla extract, turmeric polysaccharides and a radix paeoniae alba extract in a weight ratio of 1: (0.1-5): (1-10). The in-vitro MTT (Methylthiazolyl Tetrazolium) assay activity tests proves that traditional Chinese medicine composition provided by the invention is capable of obviously inhibiting the growth of lung cancer cell lines such as LA795 and liver cancer cell lines such as Hep-B3; and lung adenocarcinoma and hepatocellular carcinoma-bearing mice model tests show that the anti-tumor rates of the traditional Chinese medicine composition both are more than 50%, and the traditional Chinese medicine composition is capable of improving the spleen index and the liver index of the mice, and obviously inhibiting pulmonary metastasis of subcutaneously transplanted tumors of the mice and causing apoptosis of tumor cells without any obvious toxic and side effects. Compared with single use of each raw material, the medicine composition is higher in anti-lung cancer and anti-liver cancer activity and clear in action, and has excellent inhibition effect on the lung cancer and the liver cancer.

The invention provides a method for establishing a mice transplantable breast cancer experimental pulmonary metastasis model. The method comprises the following steps: grinding mice spontaneous breast cancer adenoma in a mesh screen, carrying out centrifugal precipitation, preparing a tumour cell suspension with the cell concentration of (1-2)*107 cell / mL by the use of a nutrient solution, carrying out tail intravenous injection on each mouse by the use of 0.1-0.3mL of the tumour cell suspension, feeding the mice under normal conditions and normally breeding for 25-35 days to finish the pulmonary metastasis model. The injected tumor cells are prepared by grinding genuine C3H mice tumor cells in mice, thus better simulating the in vivo metastasis process. According to the breast cancer experimental metastasis model, tumour cells are directly injected into animal bodies through a tail intravenous injection mode; after the injection, animals are raised under normal conditions without special environment; and after transplantation, it is detected that metastatic lesions are formed in C3H mice lungs through blood circulation. The method provided by the invention has advantages of high incidence rate, short tumour formation time, high incidence rate of metastasis and low cost, etc.

The invention discloses a human Ewing's sarcoma cell line, named as human drug-resistant Ewing's sarcoma cell SGH-01, which is preserved in China center for type culture collection (CCTCC) at 18 October, 2018, and the preservation number is CCTCC NO: C2018222. A donor of the cell line is clinically drug-resistant Ewing's sarcoma patients, the cell line has doxorubicin resistance, the nude mouse subcutaneous tumor formation ability, and the shin bone in-situ tumor formation ability, and nude mouse shin bone in-situ tumors have the pulmonary metastasis ability. The cell line can become experimental materials for researchers to deeply develop Ewing's sarcoma drug resistance and metastasis mechanisms and find / evaluate treatment schemes.

The invention relates to applications of a regulator of calcineurin 1.4 (RCAN1.4) or analogues of RCAN1.4 in preparing medicines for inhibiting liver cancer. According to the applications, RCAN1.4 orup-regulators of RCAN1.4 can be used for inhibiting liver cancer; and the functional analogue medicines such as cyclosporin A of RCAN1.4 also can obviously reduce the in-vivo pulmonary metastasis capacity of liver cancer cells.

The invention relates to materia medica, molecular medicine and disease prevention fields, in particular to a gene medicine based on recombinant adeno-associated virus and tumor angiogenesis inhibiting gene. The medicine can target at lung tissue and inhibit effectively cancer metastasis and the occurrence of pulmonary metastases.

The invention provides an oral squamous carcinoma cell strain as well as a preparation method and applications of the oral squamous carcinoma cell strain. The oral squamous carcinoma cell strain is derived from the MAL- / -C57BL / 6 mouse oral carcinoma tissue induced by drinking water containing 4-nitroquinoline-1 oxide. Through primary culture on the tumor tissue, the tumour cell is subjected to continuous subculture in vitro and grows lively. Through the monoclonal screening method, the oral squamous carcinoma cell strain is obtained, the cell strain can be cultured continuously in vitro and grows lively, and the following biological characteristics of the cell are analyzed: cell proliferation, growth curve, cell cycle and apoptosis, plate colony and migration, and the in-vivo tumor formation and pulmonary metastasis capacity of the nude mouse. The result proves that the oral squamous carcinoma cell strain has the typical biological characteristics of the tumor cell, can be taken as the cell model for researching the generation, development and metastasis mechanism of oral carcinoma, and also can be taken as a tool for screening or developing anti-cancer drugs.

The invention relates to a passive solid tumor-targeted anticancer prodrug and a preparation method thereof, belonging to the field of antitumor drugs. The preparation method includes the following steps: reacting low molecular weight pectin with Mw of 5,000-45,000 with doxorubicin to obtain a pectin-doxorubicin conjugate with Mw of 100,000-1,000,000, preparing the conjugate into a suspension, and treating the suspension in an ultra-high pressure nano homogenizer to obtain the passive solid tumor-targeted anticancer prodrug with particle size of 100 nm-200 nm and melting point of 220-245°, wherein the pectin and doxorubicin are linked by an amide bond, and the pectin is linked by an ester bond formed by condensing carboxyl groups and hydroxyl groups of pectin molecules. Cell inhibition rate of the anticancer prodrug for humanized lung cancer cells NCI-H446 and A549 is equivalent to that of doxorubicin hydrochloride. In the efficacy research of melanoma B16 pulmonary metastasis model mice, the life span of tumor-bearing mice is 42.3±12.4 days, which is remarkably higher than that of the doxorubicin hydrochloride group (23.1±10.2 days).

The present invention relates to pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer. More specifically, the present invention relates to compositions that enhance anti-cancer immunity of the lung rather than induce death of advanced cancer, thus being effective in inhibiting, preventing or treating pulmonary metastasis of cancer.

The invention belongs to the field of biotechnologies, and relates to a gene vaccine capable of inhibiting cancer cell growth. The gene vaccine can express a cell membrane surface protein metadherin (MTDH) and thus being named as a MTDH gene vaccine. The MTDH gene vaccine is utilized for immunization in an oral way. The MTDH gene vaccine can activate an immune response of CD8+ cytotoxic T cells on breast cancer cells 4T1 expressing MTDH antigens. The MTDH gene vaccine can inhibit breast cancer cell growth and pulmonary metastasis. Through being combined with adriamycin, the MTDH gene vaccine can improve adriamycin effects of inhibiting breast cancer cell growth and pulmonary metastasis, and prolong a life of a mouse loaded with cancer. More significantly, the MTDH gene vaccine does not produce obvious damages on main organs of a human body. Therefore, the MTDH gene vaccine provides a novel approach for improvement of the existing breast cancer treatment method.

The invention discloses a pharmaceutical composition for improving the curative effect of paclitaxel rhythm chemotherapy in treatment of gastric cancer metastasis and a preparation method and an application thereof. The pharmaceutical composition comprises paclitaxel and a traditional Chinese medicine composition, wherein the traditional Chinese medicine composition is prepared from 60-120 parts of raw radix astragali, 30-60 parts of fried radix codonopsis, 10-20 parts of fried rhizoma atractylodis macrocephalae, 10-20 parts of radix angelicae sinensis, 10-20 parts of radix paeoniae alba, 30-60 parts of rhizoma sparganii, 30-60 parts of rhizoma curcumae, 10-20 parts of radix aucklandiae, 10-20 parts of pericarpium citri reticulatae and 5-10 parts of radix glycyrrhizae preparata. Accordingto the theory of traditional Chinese medicine, the traditional Chinese medicine composition is screened by adopting the theory of syndrome differentiation and treatment, and after the traditional Chinese medicine composition and paclitaxel are dosed according to a certain dosage, the curative effect of paclitaxel in treatment of gastric cancer pulmonary metastasis can be remarkably improved. Bonemarrow suppression caused by paclitaxel and immune function damage caused by paclitaxel can be remarkably relieved; and unexpected technical effects of very good synergistic effect, reduction of adverse effects of paclitaxel and the like are achieved.

The invention discloses application of platycodin D to preparation of a drug for treating melanoma metastasis. Platycodin D can be used for remarkably inhibiting melanoma metastasis and has the effects of reducing the in-vitro cellular activity of melanoma, inhibiting cell migration and invasion capacities of the melanoma, inhibiting the adhesive capacity of a melanoma cell and a vascular endothelial cell and reducing the amount of pulmonary metastasis foci in bodies of rats. A pharmacodynamic method proves that platycodin D has the advantages of multiple approaches and multiple target points in anti-tumor metastasis, so that the clinical application of platycodin D on the aspect of anti-tumor metastasis has the scientific basis.

The invention discloses application of hsa_circ_0007444 in preparation of a medicine for treating ovarian cancer. According to the research, a hsa_circ_0007444 overexpression plasmid vector is prepared, and the function of the hsa_circ_0007444 overexpression plasmid vector in ovarian cancer cells is verified by overexpression lentivirus and specific siRNA. The overexpression hsa_circ_0007444 can obviously inhibit proliferation, invasion and migration of ovarian cancer and promote apoptosis of ovarian cancer, and knockdown of hsa_circ_0007444 can obviously promote proliferation, invasion and migration of ovarian cancer and inhibit apoptosis of ovarian cancer. Meanwhile, hsa_circ_0007444 overexpression can inhibit growth and lung metastasis of ovarian cancer in vivo and is an important target for treating ovarian cancer.

The invention discloses a pulmonary-metastasis-derived high-metastasis human ovarian cancer cell line as well as establishment and an application thereof. The pulmonary-metastasis-derived high-metastasis human ovarian cancer cell line is named as high-metastasis human ovarian cancer cell line A2780-M which is preserved in CCTCC (China Center for Type Culture Collection) on Jan 22, 2017 with the preservation number being CCTCC NO: C201719. The high-metastasis human ovarian cancer cell line A2780-M is derived from human ovarian cancer cell line A2780, has more obvious proliferation activity and stronger metastasis function, invasion function and cell movement capacity than a maternal line, can serve as a reliable high-metastasis human ovarian cancer cell line and animal model for researching a molecular mechanism of ovarian cancer metastasis and can further provide a new target for clinical diagnosis and treatment, drug screening and prognosis.

The invention discloses a bispecific fusion protein containing a cytokine IL-15 and a CD40 antibody or an immunocompetence fragment and a preparation method and application of the bispecific fusion protein. The fusion protein comprises the human CD40 antibody and the cytokine IL-15 with different structural formulas, and is obtained by co-transfection and expression of different plasmids. The fusion protein disclosed by the invention can activate APC cells, T cells and NK cells at the same time, and the tumor targeting property of the cytokine is enhanced; DC cell maturation and IL-12 secretion can be stimulated, the growth of mouse melanoma can be significantly inhibited, and the volume and average pulmonary metastasis of the melanoma can be reduced.

The invention provides a tetrahydrofuran substituted uracil compound for treating liver cancer as well as a pharmaceutical composition and application thereof. The tetrahydrofuran substituted uracil compound has a following chemical structure shown as a formula A. The structural formula is as shown in the description. The tetrahydrofuran substituted uracil compound disclosed by the invention has high inhibitory activity, is capable of interfering synthesis of tumor cell DNA and proteins thereof in vivo so as to inhibit tumor formation and growth of the liver cancer, and can further obviously inhibit pulmonary metastasis and intrahepatic dissemination of the liver cancer.

The invention provides a preparation method of a lung hardness base in vitro cell culture platform. The preparation method comprises the steps of mixing rat tail I type collagen with DMEM basic culture mediums in different volume ratios, and performing placing in a first perforated plate; mixing the rat tail I type collagen with DMEM basic culture fluid and CM-LV-LOXL2-OE in the volume ratio being1 to 10 to 5, and performing placing in a second perforated plate; putting the first perforated plate and the second perforated plate in an incubator of 37 DEG C for standing; and placing a base after colloid formation in a refrigerator of 4 DEG C, and after 10-14h, forming an in vitro cell culture platform having different base hardness. Through the adoption of the preparation method disclosed by the invention, the hardness changes of in vivo low-hardness internal organ tissue of which the hardness is smaller than 1KPa can be well simulated, and a novel in vitro research platform is providedfor seeking the general molecular characteristics of entity tumorigenesis pulmonary metastasis and discussing a pathomechanism about transferring target organs to be re-modeled and reformed into appropriate soil.

The invention discloses a method for constructing a breast cancer MCF7 cell line capable of stably over-expressing exogenous recombinant plasmid pCDH-puro-PRMT7. The full length of a PRMT7 gene is obtained; the pCDH-puro-PRMT7 plasmid is constructed; a virus is packaged, and cells are infected by the virus; puromycin is screened; and the MCF7 cell line capable of stably over-expressing the PRMT7 is obtained after amplification. The construction of the cell line is good for researching the cell biological functions of the PRMT7, such as the influences of the PRMT7 on the tumorigenic abilities of mice and the influences on the pulmonary metastasis abilities of the mice.

The invention discloses application of an SMS2 inhibitor in preparation of a medicine for treating highly invasive breast cancer. An overall experiment of establishing a mouse triple negative breast cancer model by utilizing 4T1 cells and an in-vitro experiment performed by adopting mouse primary bone marrow macrophages prove that the compound I serving as an SMS2 specific inhibitor can be used for effectively inhibiting type 2 polarization of macrophages by reducing activity of in-vivo sphingomyelin synthase 2 and sphingomyelin level, the tumor microenvironment is remodeled by reducing the infiltration degree of M2 type macrophages and other bone marrow-derived immunosuppressive cells in the tumor microenvironment of the triple negative breast cancer, so that the in-situ growth of the triple negative breast and the formation and growth of pulmonary metastases caused by menstruation are inhibited. Inhibition of SMS2 activity can be used for preventing and treating highly invasive malignant breast cancer including triple negative breast cancer.

The invention provides a human osteosarcoma pulmonary metastasis primary cell strain and a culture method and application thereof. The human osteosarcoma pulmonary metastasis primary cell strain is named as ZOSL-1, and the preservation number is CCTCC No: C202088. The human osteosarcoma pulmonary metastasis primary cell strain is obtained by combining a pancreatin differential digestion method, adifferential adherence method and a serum-free medium stimulation method and screening purified tumor cells, can be used for osteosarcoma pulmonary metastasis mechanism research and antitumor drug research and has good medical value.

The invention discloses an application of alkane compound pristane as an immunopotentiator in preparation of drugs for preventing and treating solid tumors. The invention finds for the first time thatthe natural compound alkane compound pristane can be used for preparing a systemic immunopotentiator, and finds the application of the systemic immunopotentiator in preparation of the drugs for preventing and treating solid tumors. The invention proves that the low-dose pristane can be used for effectively preventing breast tumors, inhibiting lung metastasis of the breast tumors, improving prognosis survival, effectively inhibiting liver metastasis and lung metastasis of melanoma, and increasing depilation-free survival rate. Research results show that enhancing the overall immunity is an effective strategy for preventing and treating solid tumors. In addition, the invention finds and proves that the alkane compound pristane can become a novel potential medicine for preventing and treating solid tumors.

The present invention relates to a pharmaceutical composition enabling the prevention or treatment of cancer metastasis to the lung and, more specifically, to a composition which enhances the immunityof the lung against cancer rather than inducing apoptosis of existing cancer, thereby enabling effective inhibition, prevention or treatment of cancer metastasis to the lung after the cancer occurs.

The invention relates to an application of miR-491 in preparing medicines for treating osteosarcoma. According to the application, miR-491 is used for preparing medicines for inhibiting osteosarcoma growth, pulmonary metastasis and pulmonary metastatic relapse. MiR-491 and a pharmaceutically acceptable carrier are bonded, and the bonded MiR-491 and pharmaceutically acceptable carrier are compounded with antitumor drugs and / or pharmaceutically acceptable auxiliary materials to prepare the medicinal composition. For the medicinal composition, miR-491 is adopted as the active ingredient, whereinthe nucleotide sequence of miR-491 is shown as SEQ ID No.1. The medicinal composition contains miR-491 bonded to the carrier and / or the pharmaceutically acceptable auxiliary materials. The in-vivo andin-vitro experiments prove that after overexpression of miR-491, the growth of osteosarcoma and pulmonary metastasis can be effectively inhibited, the inhibiting effect and apoptosis-promoting effectof cis-platinum for osteosarcoma cells can be promoted, which means that miR-491 enhances the anticancer effect of platinum-containing medicines, and can be used for preparing novel treatment medicines for treating osteosarcoma cell pulmonary metastasis, and thus possibility is provided for clinical treatment of pulmonary metastatic osteosarcoma.